{"id":17735,"date":"2015-09-10T00:00:00","date_gmt":"2015-09-10T00:00:00","guid":{"rendered":"https:\/\/cadca1stg.wpengine.com\/resource\/senators-call-for-investigation-into-fda-decision-on-oxycontin\/"},"modified":"2015-09-10T00:00:00","modified_gmt":"2015-09-10T00:00:00","slug":"senators-call-for-investigation-into-fda-decision-on-oxycontin","status":"publish","type":"resource","link":"https:\/\/www.cadca.org\/es\/resource\/senators-call-for-investigation-into-fda-decision-on-oxycontin\/","title":{"rendered":"Senadores piden que se investigue la decisi\u00f3n de la FDA sobre Oxycontin"},"content":{"rendered":"<p>Los senadores Joe Manchin (DW.V.), Tim Kaine (D-Va.) y Mark Warner (D-Va.) enviaron una carta al presidente del Comit\u00e9 de Salud, Educaci\u00f3n, Trabajo y Pensiones (HELP), Lamar Alexander (R-Tenn .) y la miembro de alto rango Patty Murray (D-Wash.) pidiendo una investigaci\u00f3n sobre la decisi\u00f3n de la Administraci\u00f3n de Alimentos y Medicamentos (FDA) de aprobar OxyContin para su uso en ni\u00f1os de hasta 11 a\u00f1os y un examen del aumento en el mal uso, abuso y muertes por sobredosis de opi\u00e1ceos.<\/p>\n<p>\u201cLa decisi\u00f3n de la FDA de recetar OxyContin a ni\u00f1os de hasta 11 a\u00f1os es un ejemplo aterrador de la desconexi\u00f3n entre el proceso de aprobaci\u00f3n de la agencia y las realidades que la epidemia mortal de abuso de medicamentos recetados est\u00e1 teniendo en nuestras comunidades\u201d, dijo Manchin. en un comunicado de prensa.<strong> <\/strong>\u201cEl Senado debe actuar con rapidez para examinar esta decisi\u00f3n, que se tom\u00f3 sin el asesoramiento de un comit\u00e9 asesor independiente, y analizar la epidemia de abuso de opi\u00e1ceos de manera m\u00e1s amplia\u201d.<\/p>\n<p>\u201cEn agosto, viaj\u00e9 por el Commonwealth y escuch\u00e9 a los l\u00edderes locales, las fuerzas del orden y los profesionales m\u00e9dicos hablar sobre el impacto que est\u00e1 teniendo el abuso de opioides en nuestras comunidades\u201d, dijo Kaine en un comunicado de prensa. \u201cLa prescripci\u00f3n excesiva y el uso indebido de opioides ha contribuido a la crisis de abuso de drogas, y me preocupa profundamente que la decisi\u00f3n de la FDA de aprobar OxyContin para ni\u00f1os de hasta 11 a\u00f1os de edad complique a\u00fan m\u00e1s esta epidemia\u201d.<\/p>\n<p>\u201cEl aumento exponencial del abuso de opi\u00e1ceos est\u00e1 devastando a Virginia y al resto del pa\u00eds. Me preocupa la decisi\u00f3n de la FDA de expandir la poblaci\u00f3n aprobada que usa estos medicamentos adictivos para incluir a ni\u00f1os de hasta 11 a\u00f1os. Me preocupa especialmente que esta decisi\u00f3n se haya tomado sin el consejo de un comit\u00e9 asesor independiente, que es requerido por las regulaciones de la FDA en casos como estos\u201d.<strong> <\/strong>Warner dijo en un comunicado de prensa. \u201cUna investigaci\u00f3n exhaustiva proporcionar\u00e1 responsabilidad y transparencia sobre c\u00f3mo se tom\u00f3 esta decisi\u00f3n\u201d.<\/p>\n<p>La carta tambi\u00e9n fue firmada por los senadores Jeanne Shaheen (DN.H.), Bill Nelson (D-Fla.), Ed Markey (D-Mass.), Kelly Ayotte (RN.H.), Angus King (I-Maine) y Claire McCaskill (D-Mo.).<\/p>\n<p><strong>VER TAMBI\u00c9N:<\/strong><\/p>\n<p>Curso en l\u00ednea de CADCA: \u201cAplicando el Marco Estrat\u00e9gico de Prevenci\u00f3n al Abuso de Medicamentos Recetados\u201d<\/p>\n<p>\u00a0<\/p>","protected":false},"excerpt":{"rendered":"<p>Senators Joe Manchin (D-W.V.), Tim Kaine (D-Va.) and Mark Warner (D-Va.) sent a letter to the Health, Education, Labor and<\/p>","protected":false},"author":23,"featured_media":0,"template":"","resource_type":[281],"drug_specific_issues":[307],"action_to_do":[],"class_list":["post-17735","resource","type-resource","status-publish","hentry","resource_type-coalitions-online","drug_specific_issues-prescription-and-over-the-counter-medications"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Senators Call for Investigation into FDA Decision on Oxycontin | CADCA<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cadca.org\/es\/resource\/senators-call-for-investigation-into-fda-decision-on-oxycontin\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Senators Call for Investigation into FDA Decision on Oxycontin | CADCA\" \/>\n<meta property=\"og:description\" content=\"Senators Joe Manchin (D-W.V.), Tim Kaine (D-Va.) and Mark Warner (D-Va.) sent a letter to the Health, Education, Labor and\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cadca.org\/es\/resource\/senators-call-for-investigation-into-fda-decision-on-oxycontin\/\" \/>\n<meta property=\"og:site_name\" content=\"CADCA\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cadca.org\/wp-content\/uploads\/2022\/03\/cadca-member-of-logo1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"880\" \/>\n\t<meta property=\"og:image:height\" content=\"500\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.cadca.org\\\/resource\\\/senators-call-for-investigation-into-fda-decision-on-oxycontin\\\/\",\"url\":\"https:\\\/\\\/www.cadca.org\\\/resource\\\/senators-call-for-investigation-into-fda-decision-on-oxycontin\\\/\",\"name\":\"Senators Call for Investigation into FDA Decision on Oxycontin | CADCA\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.cadca.org\\\/#website\"},\"datePublished\":\"2015-09-10T00:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.cadca.org\\\/resource\\\/senators-call-for-investigation-into-fda-decision-on-oxycontin\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.cadca.org\\\/resource\\\/senators-call-for-investigation-into-fda-decision-on-oxycontin\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.cadca.org\\\/resource\\\/senators-call-for-investigation-into-fda-decision-on-oxycontin\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.cadca.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Senators Call for Investigation into FDA Decision on Oxycontin\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.cadca.org\\\/#website\",\"url\":\"https:\\\/\\\/www.cadca.org\\\/\",\"name\":\"CADCA\",\"description\":\"The Premier Prevention Association\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.cadca.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Senators Call for Investigation into FDA Decision on Oxycontin | CADCA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cadca.org\/es\/resource\/senators-call-for-investigation-into-fda-decision-on-oxycontin\/","og_locale":"es_ES","og_type":"article","og_title":"Senators Call for Investigation into FDA Decision on Oxycontin | CADCA","og_description":"Senators Joe Manchin (D-W.V.), Tim Kaine (D-Va.) and Mark Warner (D-Va.) sent a letter to the Health, Education, Labor and","og_url":"https:\/\/www.cadca.org\/es\/resource\/senators-call-for-investigation-into-fda-decision-on-oxycontin\/","og_site_name":"CADCA","og_image":[{"width":880,"height":500,"url":"https:\/\/www.cadca.org\/wp-content\/uploads\/2022\/03\/cadca-member-of-logo1.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.cadca.org\/resource\/senators-call-for-investigation-into-fda-decision-on-oxycontin\/","url":"https:\/\/www.cadca.org\/resource\/senators-call-for-investigation-into-fda-decision-on-oxycontin\/","name":"Senators Call for Investigation into FDA Decision on Oxycontin | CADCA","isPartOf":{"@id":"https:\/\/www.cadca.org\/#website"},"datePublished":"2015-09-10T00:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.cadca.org\/resource\/senators-call-for-investigation-into-fda-decision-on-oxycontin\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cadca.org\/resource\/senators-call-for-investigation-into-fda-decision-on-oxycontin\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.cadca.org\/resource\/senators-call-for-investigation-into-fda-decision-on-oxycontin\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cadca.org\/"},{"@type":"ListItem","position":2,"name":"Senators Call for Investigation into FDA Decision on Oxycontin"}]},{"@type":"WebSite","@id":"https:\/\/www.cadca.org\/#website","url":"https:\/\/www.cadca.org\/","name":"CADCA","description":"The Premier Prevention Association","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cadca.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"}]}},"_links":{"self":[{"href":"https:\/\/www.cadca.org\/es\/wp-json\/wp\/v2\/resource\/17735","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cadca.org\/es\/wp-json\/wp\/v2\/resource"}],"about":[{"href":"https:\/\/www.cadca.org\/es\/wp-json\/wp\/v2\/types\/resource"}],"author":[{"embeddable":true,"href":"https:\/\/www.cadca.org\/es\/wp-json\/wp\/v2\/users\/23"}],"version-history":[{"count":0,"href":"https:\/\/www.cadca.org\/es\/wp-json\/wp\/v2\/resource\/17735\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.cadca.org\/es\/wp-json\/wp\/v2\/media?parent=17735"}],"wp:term":[{"taxonomy":"resource_type","embeddable":true,"href":"https:\/\/www.cadca.org\/es\/wp-json\/wp\/v2\/resource_type?post=17735"},{"taxonomy":"drug_specific_issues","embeddable":true,"href":"https:\/\/www.cadca.org\/es\/wp-json\/wp\/v2\/drug_specific_issues?post=17735"},{"taxonomy":"action_to_do","embeddable":true,"href":"https:\/\/www.cadca.org\/es\/wp-json\/wp\/v2\/action_to_do?post=17735"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}